within Pharmacolibrary.Drugs.ATC.A;

model A06AH05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0003578333333333333,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.155,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.143,
    k12             = 51.5,
    k21             = 51.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AH05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Naldemedine is a peripherally-acting μ-opioid receptor antagonist (PAMORA) used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. It is an approved prescription medication, generally well-tolerated, and intended for oral administration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following a single oral dose of 0.2 mg.</p><h4>References</h4><ol><li><p>Fukumura, K, et al., &amp; Kawasaki, A (2020). The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. <i>Clinical pharmacology in drug development</i> 9(2) 162–174. DOI:<a href=\"https://doi.org/10.1002/cpdd.690\">10.1002/cpdd.690</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30977959/\">https://pubmed.ncbi.nlm.nih.gov/30977959</a></p></li><li><p>Fukumura, K, et al., &amp; Ogura, E (2020). Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects. <i>Clinical drug investigation</i> 40(6) 529–540. DOI:<a href=\"https://doi.org/10.1007/s40261-020-00902-w\">10.1007/s40261-020-00902-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32323104/\">https://pubmed.ncbi.nlm.nih.gov/32323104</a></p></li><li><p>Ohnishi, S, et al., &amp; Wajima, T (2019). Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 49(9) 1044–1053. DOI:<a href=\"https://doi.org/10.1080/00498254.2018.1536815\">10.1080/00498254.2018.1536815</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30351180/\">https://pubmed.ncbi.nlm.nih.gov/30351180</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AH05;
